Share Price:

APNASPENAspen Pharmacare Hldgs22071428 (1.98%)

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform to be released on 4 March 2024.

Aspen Invests R2.7 Billion in Expanding Global Business

Johannesburg – JSE listed Aspen Pharmacare Holdings Limited (Apn) has announced an investment by its offshore subsidiary, Aspen Global Incorporated, of GBP 170 million (approximately R2.7 billion) for the acquisition of four pharmaceutical products from GlaxoSmithKline (GSK). Aspen Global has acquired the intellectual property rights to the branded pharmaceuticals Eltroxin, Imuran, Lanoxin and Zyloric for… Continue reading Aspen Invests R2.7 Billion in Expanding Global Business

Aspen wins significant portion of ARV tender

In addition to maintaining the supply contract for existing tender items, Aspen has also secured volumes for two new products, Aspen Efavirenz and Tenofivir. Tenofivir is a key new molecule to the ARV tender. Increased usage is anticipated over the tender period. Aspen secured more than 50% by volume of the entire ARV tender based… Continue reading Aspen wins significant portion of ARV tender

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.